



The Latest Prescription Trends for Controlled Prescription Drugs

September 1, 2015 Christopher M. Jones PharmD, MPH Senior Advisor Office of Public Health Strategy and Analysis Office of the Commissioner Food and Drug Administration



Overview

- Data source
- Opioid analgesics
- Benzodiazepines
- Stimulants
- Opioid use disorder medication assisted treatments
- Conclusions



Data Source


- Data from IMS Health
 - National Prescription Audit
 - National Prescription Audit Extended Insights



OPIOID ANALGESICS




Opioid analgesic prescriptions dispensed from US retail pharmacies, Q42009-Q22015






Opioid analgesic prescriptions dispensed from US retail pharmacies for select opioids, Q42009-Q22015 % of All Opioids



Source: IMS Health National Prescription Audit, Data Extracted 8/24/2015




Opioid analgesic prescriptions dispensed from US retail pharmacies by provider specialty, 2010-2014






Percentage of opioid analgesic prescriptions dispensed from US retail pharmacies by specialty, 2010 vs 2014

2010 2014






Opioid analgesic prescriptions dispensed from US retail pharmacies by gender, August 2014-July 2015





10

Opioid analgesic prescriptions dispensed from US retail pharmacies by age group, August 2014-July 2015




Source: IMS Health National Prescription Audit Extended Insights Data Extracted 8/24/2015



BENZODIAZEPINES



Benzodiazepine prescriptions dispensed from US retail pharmacies, Q42009-Q22015





Benzodiazepine prescriptions dispensed from US retail pharmacies by provider specialty, 2010-2014

■ 2010 ■ 2011 ■ 2012 ■ 2013 ■ 2014 60,000,000 50,000,000 Number of dispensed prescriptions 40,000,000 30,000,000 20,000,000 10,000,000 0 **Primary Care Physicians** Nurse Practitioners/Physician Psychiatrist/Psychologists Other 13


Assistants

Source: IMS Health National Prescription Audit, Data Extracted 8/24/2015



Percentage of benzodiazepine prescriptions dispensed from US retail pharmacies by specialty, 2010 vs 2014


2010 2014



Source: IMS Health National Prescription Audit, Data Extracted 8/24/2015




Benzodiazepine prescriptions dispensed from US retail pharmacies by gender, August 2014-July 2015





16

Benzodiazepine prescriptions dispensed from US retail pharmacies by age group, August 2014-July 2015



Source: IMS Health National Prescription Audit Extended Insights Data Extracted 8/24/2015




STIMULANTS



18


Stimulant* prescriptions dispensed from US retail pharmacies, Q42009-Q22015



* includes: amphetamine, amphetamine-dextroamphetamine, dextroamphetamine,, dexmethylphenidate, lisdexamfetamine, methamphetamine, methylphenidate, pemoline Source: IMS Health National Prescription Audit, Data Extracted 8/24/2015



Stimulant* prescriptions dispensed from US retail pharmacies by provider specialty, 2010-2014




* includes: amphetamine, amphetamine-dextroamphetamine, dextroamphetamine,, dexmethylphenidate, lisdexamfetamine, methamphetamine, methylphenidate, pemoline Source: IMS Health National Prescription Audit, Data Extracted 8/24/2015



Percentage of stimulant* prescriptions dispensed from US retail pharmacies by specialty, 2010 vs 2014


2010 2014



* includes: amphetamine, amphetamine-dextroamphetamine, dextroamphetamine,, dexmethylphenidate, lisdexamfetamine, methamphetamine, methylphenidate, pemoline Source: IMS Health National Prescription Audit, Data Extracted 8/24/2015



Stimulant* prescriptions dispensed from US retail pharmacies by gender, August 2014-July 2015




*includes: amphetamine, amphetamine-dextroamphetamine, dextroamphetamine,, dexmethylphenidate, lisdexamfetamine, methamphetamine, methylphenidate, 21 Pemoline, modafinil, armodafinil, caffeine,

Source: IMS Health National Prescription Audit Extended Insights Data Extracted 8/24/2015



Pemoline, modafinil, armodafinil, caffeine,

Stimulant* prescriptions dispensed from US retail pharmacies by age group, August 2014-July 2015




Source: IMS Health National Prescription Audit Extended Insights Data Extracted 8/24/2015

OPIOID USE DISORDER MEDICATION ASSISTED TREATMENTS





Buprenorphine* prescriptions dispensed from US retail pharmacies, Q42009-Q22015




*Does not include Butrans or Buprenex (or generics) Source: IMS Health National Prescription Audit, Data Extracted 8/24/2015



Percentage of buprenorphine* prescriptions dispensed from US retail pharmacies by specialty, 2010 vs 2014

2010 2014




*Does not include Butrans or Buprenex (or generics) Source: IMS Health National Prescription Audit, Data Extracted 8/24/2015



Number of dispensed prescriptions

Naltrexone* prescriptions dispensed from US retail pharmacies; Q42009-Q22015




* Naltrexone is also approved for use in alcohol dependence. Thus, not all prescriptions were used for opioid dependence
+The number of prescriptions dispensed for Vivitrol from specialty pharmacies is approximately 3-4x that from US retail pharmacies.
Source: IMS Health National Prescription Audit, Data Extracted 8/24/2015



Percentage of naltrexone* prescriptions dispensed from US retail pharmacies⁺ by specialty, 2010 vs 2014

2010 2014



* Naltrexone is also approved for use in alcohol dependence. Thus, not all prescriptions were used for opioid dependence
+The number of prescriptions dispensed for Vivitrol from specialty pharmacies is approximately 3-4x that from US retail pharmacies.
Source: IMS Health National Prescription Audit, Data Extracted 8/24/2015



Conclusions

- The number of prescriptions dispensed for opioid analgesics has declined in recent years
- The number of prescriptions dispensed for benzodiazepines has been relatively consistent
- The number of prescriptions dispensed for stimulants has increased in recent years
- The number of prescriptions dispensed for both naltrexone and buprenorphine has increased in recent years
- There is variation in prescribing by provider specialty and patient gender and age across the examined drug classes





Questions?

Christopher.M.Jones@fda.hhs.gov

The findings in this presentation do not represent the official position of the US Food and Drug Administration, the Department of Health and Human Services, or the U.S. Government